Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2025-12-25 @ 4:06 AM
NCT ID:
NCT01440920
Eligibility Criteria:
Key Inclusion Criteria:
* Patients with acute myeloid leukemia including patients with secondary leukemia. However, the patients with MDS apparently evolved itno AML and patients with AML accompanied by t(15;17)(q22;q12),(PML/RARalpha) , should be excluded.
* Patients who achieved the first complete remission after the induction regimen and finished a standard consolidation therapy.
* Age: ≥ 60years of age(at the time of signature of the informed consent form)
* Sex: Male and Female
* Patients who are capable of giving informed consent
* Patient's blasts cells show expression of WT1mRNA, detected by quantitative RT-PCR.
* Patients must be one of the following HLA DRB1 types: HLA-DRB1\*01:01, \*04:05, \*15:01, \*15:02, \*08:03 and \*09:01.
Key Exclusion Criteria:
* Patients who are scheduled for a bone marrow transplantation
* Patients who were administered exceeded acceptable therapeutic dose of immunosuppressants and adrenal cortical steroids.
* Patients with uncontrollable active infectious diseases
* Patients with autoimmune diseases (including Hashimoto's disease, idiopathic thrombocytopenic purpura, and autoimmune hepatitis) or with a medical history of active autoimmune diseases
* Immunocompetent patients
* Patients with a complication of interstitial pneumonia or with a medical history of interstitial pneumonia
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
60 Years
Study:
NCT01440920
Study Brief:
Protocol Section:
NCT01440920